DBV Technologies S.A.

NASDAQ: DBVT · Real-Time Price · USD
8.96
-0.37 (-3.97%)
At close: May 22, 2025, 12:07 PM

Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.

Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis.

Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes.

The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.

DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.
DBV Technologies S.A. logo
Country FR
IPO Date Oct 22, 2014
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Daniel Tassé

Contact Details

Address:
177-181 Avenue Pierre Brossolette
Montrouge,
FR
Website https://www.dbv-technologies.com

Stock Details

Ticker Symbol DBVT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001613780
CUSIP Number 23306J101
ISIN Number US23306J1016
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Daniel Tassé Chief Executive Officer & Director
Michele F. Robertson Chief Legal Officer
Virginie Simone Jeanine Verrechia Boucinha M.B.A. Chief Financial Officer
Alan Kerr Senior Vice President & Head of Global Regulatory Affairs
Caroline Daniere Chief Human Resources Officer & Chief of Staff
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. Chief Operations Officer
Dr. Pharis Mohideen M.D. Chief Medical Officer
Dr. Robert G. Pietrusko Pharm. D., Pharm.D. Chief Regulatory Officer
Katie Matthews Investor Relations Officer
Pascal Wotling Chief External Manufacturing & Supply Chain Officer

Latest SEC Filings

Date Type Title
May 20, 2025 3 Filing
May 19, 2025 S-3 Filing
May 15, 2025 ARS Filing
May 15, 2025 DEF 14A Filing
May 14, 2025 10-K/A [Amend] Annual Report
May 05, 2025 PRE 14A Filing
Apr 30, 2025 8-K Current Report
Apr 30, 2025 10-Q Quarterly Report
Apr 28, 2025 10-K/A [Amend] Annual Report
Apr 24, 2025 3 Filing